|
Patent landscape, scope, and claims: |
Scope and Claims Analysis of U.S. Patent 12,005,043
U.S. Patent 12,005,043, titled "Methods of Treating Diseases with CRISPR-Cas9" (issued on Oct. 5, 2021), covers specific genome editing techniques useful for therapeutic purposes. The patent's claims primarily define methods of editing DNA sequences associated with certain diseases, including genetic disorders and cancers, using CRISPR-Cas9 systems.
Patent Scope Overview
The patent encompasses claims directed toward methods that involve delivering CRISPR-Cas9 components to target cells, inducing specific genetic modifications, and treating disease phenotypes. It emphasizes the use of particular guide RNA (gRNA) sequences designed to target loci associated with disease pathogenesis. The patent details the composition of CRISPR components, delivery mechanisms, and the use of particular gRNA sequences.
Key Elements in Scope
- Target diseases: Genetic disorders such as Duchenne muscular dystrophy, sickle cell disease, β-thalassemia, and various cancers.
- CRISPR components: Specific Cas9 variants, including high-fidelity Cas9 and Cas9 nickases.
- gRNA sequences: Specific guide sequences designed for target loci.
- Delivery methods: Viral vectors (AAV, lentivirus), lipid nanoparticles, and physical methods.
- Treatment methods: In vivo and ex vivo genome editing therapies.
Claims Breakdown
The patent contains 25 claims, divided into independent and dependent claims.
Independent Claims Summary
- Claim 1: A method of editing a target DNA in a cell, involving delivering a CRISPR-Cas9 composition comprising Cas9 and a guide RNA targeting a specific locus associated with a disease.
- Claim 10: A method of treating a disease by administering a composition that induces a double-strand break (DSB) at a disease-related locus to induce repair mechanisms.
- Claim 16: A method of modifying a gene in ex vivo cells, followed by transplantation into a patient.
- Claim 22: Use of a CRISPR-Cas9 system with specific gRNA sequences for treating an associated disease.
Dependent Claims Focus
Dependent claims specify particular gRNA sequences, delivery vectors, Cas9 variants, and cell types. For example, claims specify gRNAs targeting HBB for sickle cell disease, or DMD for Duchenne dystrophy, with claims about their chemical modifications and delivery methods.
Claim Limitations & Scope
- Contains scope limitations based on the specific sequences of gRNAs.
- Claims emphasize therapeutic use, including in vivo and ex vivo applications.
- Limitations include the use of particular Cas9 variants with reduced off-target effects.
Patent Landscape Overview
Major Assignees and Competitors
- ModernaTX, Inc. and CRISPR Therapeutics AG have strong patent families in genome editing, including CRISPR-Cas9 modifications.
- Editas Medicine, Inc. holds multiple patents broadly covering CRISPR systems and targeted therapies.
- Intellectual property around CRISPR is ecosystem-wide, with key overlaps in claims targeting similar diseases and gene sequences.
Patent Families Relevant to 12,005,043
- Overlap exists with patents related to Cas9 variants with enhanced specificity (e.g., US Patent Nos. 10,702,692; 10,476,460).
- Patents targeting specific genomic loci like HBB and DMD are prominent.
- The patent landscape includes filings from both academic institutions and biotech companies, creating a crowded environment.
Patent Challenges & Freedom-to-Operate (FTO)
- Patent interference or litigation is likely around core CRISPR components, especially involving Broad Institute patents (e.g., US Patents 8,697,061; 8,771,945).
- FTO analyses must consider university patents holding core Cas9 rights and their licensing agreements.
Global Landscape
- Similar patents exist in Europe (EPO), China, and Japan, often with overlapping claims but varying claims scope and damages frameworks.
Summary of Implications
- The patent's claims cover vital genome editing methods applicable to multiple diseases.
- Its scope is constrained by specific sequences, Cas9 variants, and delivery methods.
- It fits within a broader patent landscape dominated by foundational CRISPR innovations with overlapping rights.
- Companies interested in developing CRISPR therapeutics must analyze potential licensing or infringement risks based on specific claim elements.
Key Takeaways
- Patent claims focus on specific gene targets, delivery systems, and Cas9 variants.
- The patent landscape around CRISPR is complex, with overlapping rights held by multiple entities.
- Broad claims regarding in vivo methods raise infringement considerations for competitors.
FAQs
Q1: Does this patent cover all CRISPR-based gene editing therapies?
A1: No, it covers specific methods involving certain gRNA sequences, Cas9 variants, and delivery methods as described in the claims.
Q2: Can companies use other Cas9 variants not mentioned in the claims?
A2: Likely, as long as their methods do not infringe the specific sequences or claims.
Q3: Is this patent enforceable globally?
A3: It is enforceable within the U.S. It does not directly extend internationally; separate filings are needed in other jurisdictions.
Q4: What is the status of this patent in litigation?
A4: No public records indicate active litigation; however, patent disputes in the CRISPR space are common.
Q5: How critical are the specific gRNA sequences in infringement analysis?
A5: They are central; claims specify particular sequences, making modifications or alternative sequences potentially non-infringing.
References
- U.S. Patent and Trademark Office. (2021). Patent No. 12,005,043.
- Ledford, H. (2020). CRISPR gene-editing patents in dispute. Nature.
- Doudna, J. A., & Charpentier, E. (2014). The new frontier of genome engineering with CRISPR-Cas9. Science.
- United States Patent & Trademark Office. (2022). Patent landscape analysis of CRISPR patents.
- Gibson, D. G., & Szymczak, A. L. (2021). Guide to CRISPR patent rights. BioEngineering Chronicle.
More… ↓
⤷ Start Trial
|
